Cannabidiol for behavioral problems in patients with Tuberous Sclerosis Complex, Sanfilippo syndrome, and Fragile X syndrome

1 1 1

What is this study about?

This study is looking at three different conditions: Tuberous Sclerosis Complex, Sanfilippo syndrome, and Fragile X syndrome. These are genetic conditions that can cause behavioral problems such as irritability, aggression, and other challenging behaviors that affect daily life. The treatment being tested is Epidyolex, which is an oral solution containing cannabidiol (also known as CBD). Participants will also receive an oral solution with beta-carotene as part of the study.

The purpose of this study is to investigate whether CBD is effective in reducing irritability and other behavioral problems in children and adults with these three conditions. The study will look at how CBD affects various aspects of behavior, including symptom severity, quality of life, anxiety, depression, mood, autism symptoms, sensory processing, parental stress, and personal goals. For those who also experience seizures, the study will track seizure frequency. The safety of the treatment will be monitored by recording any side effects and checking liver enzyme levels throughout the study.

The study uses a special design called an N-of-1 series, which means each participant will be studied individually over time. Participants will take the CBD oral solution for up to 24 weeks while maintaining their current medications and treatments stable. During this time, caregivers will complete questionnaires and keep diaries to track behavioral changes and any seizures that occur. The maximum daily dose of CBD will be 25 milligrams per kilogram of body weight. Participants need to be at least 6 years old and must have a caregiver who can provide regular reports about their behavior and well-being.

1 Medication stability period

Before starting the trial, all current medications or treatments for seizures and behavioral symptoms must remain at the same dose for one month.

This stable medication regimen must be maintained throughout the entire duration of the study.

2 Baseline assessment

At the beginning of the trial, several assessments will be completed to measure current behavioral symptoms and overall condition.

The Aberrant Behavior Checklist will be used to assess irritability and other behavioral problems.

The Clinical Global Impressions scale will measure overall symptom severity.

Additional questionnaires will evaluate anxiety, depression, mood, autism symptoms, sensory processing, and quality of life.

Personal goals will be set using Goal Attainment Scaling.

Blood tests will be performed to check liver enzyme levels, including measurements of substances called ALT, AST, and bilirubin.

If seizures occur, a seizure diary will be started to record each episode.

3 Treatment with cannabidiol

Treatment will begin with Epidyolex 100 mg/ml oral solution, which contains the active substance cannabidiol.

The medication is taken by mouth.

The specific dosage, frequency, and duration of treatment will be determined individually.

An oral solution with beta-carotene may also be used during the study.

4 Ongoing monitoring

Throughout the trial, behavioral symptoms will be regularly monitored using the same questionnaires completed at baseline.

Any side effects or adverse events will be tracked and recorded.

Blood tests will be repeated periodically to monitor liver enzyme levels and ensure safety.

If seizures occur, each episode must be recorded in the seizure diary.

A caregiver will need to be consistently available to provide reports about symptoms and behaviors.

5 Follow-up assessments

Regular assessments will be conducted to evaluate changes in irritability, behavioral problems, symptom severity, quality of life, anxiety, depression, mood, autism symptoms, and sensory processing.

Progress toward personal goals will be measured.

The level of stress experienced by parents or caregivers will be assessed.

Seizure frequency will be reviewed based on diary entries.

6 Study completion

Final assessments will be completed at the end of the trial period.

All questionnaires and measurements will be repeated to compare results with baseline values.

Final blood tests will be performed to check liver enzyme levels.

The overall effectiveness and safety of cannabidiol treatment will be evaluated based on all collected data.

Who Can Join the Study?

  • You must be at least 6 years old or older to take part in this study
  • You must have a confirmed diagnosis of one of these conditions: Tuberous Sclerosis Complex (also called TSC, a genetic condition that causes non-cancerous tumors to grow in different parts of the body), Sanfilippo syndrome (a rare inherited condition that affects the body’s ability to break down certain complex sugars), or Fragile X syndrome (also called FXS, a genetic condition that can cause learning disabilities and behavioral challenges)
  • Your diagnosis must be confirmed by specific medical tests such as genetic testing
  • You must have severe behavioral problems, which means scoring at least 4 on a medical scale called the Clinical Global Impressions scale (a tool doctors use to measure how severe symptoms are)
  • If you are taking any medications or receiving treatments for seizures (sudden bursts of electrical activity in the brain that can cause changes in behavior, movements, or consciousness) or behavioral problems, these must have been at the same dose for at least one month before starting the study
  • You must be willing to keep taking the same medications and treatments at the same doses throughout the entire study without making changes
  • You must have a caregiver (a person who regularly helps take care of you) who can attend study visits and answer questions about your symptoms and behavior

Who Cannot Join the Study?

  • The information about specific reasons why patients cannot participate in this study is not available in the provided data
  • If you are interested in participating, a doctor involved in the study would need to review your individual medical situation to determine if you meet the requirements

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Axktzijrq Uqm Amsterdam The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
01.10.2025

Trial locations

Investigated drugs:

Cannabidiol (also known as Epidyolex) is a medicine derived from the cannabis plant. It is used to help reduce behavioral problems such as irritability and other difficult behaviors in patients. In this trial, it is being tested to see if it can improve behavior in people with certain genetic conditions.

Tuberous Sclerosis Complex – Tuberous Sclerosis Complex is a genetic disorder that causes non-cancerous tumors to grow in various organs throughout the body, most commonly in the brain, skin, kidneys, heart, and lungs. The condition is present from birth and results from changes in specific genes that control cell growth and division. People with this condition often experience seizures, developmental delays, and behavioral problems including irritability and autism-like symptoms. Skin abnormalities such as light-colored patches and thickened areas may appear during childhood. The severity of symptoms varies widely from person to person, with some individuals experiencing mild effects while others have more significant challenges. Brain tumors associated with this condition can lead to learning difficulties and problems with thinking and reasoning skills.

Sanfilippo Syndrome – Sanfilippo syndrome is a rare inherited metabolic disorder where the body cannot break down certain complex sugar molecules called heparan sulfate. This occurs because the body lacks or has insufficient amounts of specific enzymes needed to process these molecules. As heparan sulfate builds up in cells throughout the body, it particularly affects the brain and nervous system. Children with this condition typically develop normally for the first few years of life before symptoms begin to appear. Behavioral problems including hyperactivity, aggression, irritability, and sleep disturbances are common features of the condition. As the condition advances, affected individuals experience progressive loss of skills they had previously learned, including speech and motor abilities.

Fragile X Syndrome – Fragile X syndrome is a genetic condition that affects brain development and is the most common inherited cause of intellectual disability and autism. The condition results from changes in a specific gene on the X chromosome that produces a protein necessary for normal brain development. Children with this syndrome often show delayed development in speech, language, and motor skills during early childhood. Behavioral characteristics include anxiety, hyperactivity, attention problems, and irritability, with many individuals also displaying features associated with autism spectrum disorder. Physical features may include a long face, large ears, and flexible joints, though these become more noticeable with age. The severity of symptoms varies considerably, with males typically more severely affected than females.

Trial ID:
2025-520846-31-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    1 1 1
    Denmark Italy The Netherlands Spain
  • Study on Metformin and Colchicine for Patients with Long COVID Symptoms

    Recruiting

    1 1 1
    Investigated diseases:
    The Netherlands